Aphria Inc., through its Canadian-based operations, cultivates, produces and distributes medical and adult-use cannabis products. Founded in 2013 and headquartered in Leamington, Ontario, the company holds licences under Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and the federal adult-use regime. Aphria operates multiple indoor and greenhouse facilities with combined capacity exceeding 3.7 million square feet, focusing on scalable, low-cost cultivation of high-quality cannabis flower.
The company’s product portfolio spans dried flower, cannabis oils, soft gels, vaporizers, concentrates and edibles, marketed under brands such as Solei, Good Supply, Big Bang Gummies and RIFF. Aphria’s manufacturing division also produces pharmaceutical-grade formulations for patient care and scientific research. Rigorous quality control and standardized cultivation protocols support its commitment to safety, consistency and product innovation.
Aphria serves a range of markets through established distribution networks across Canada as well as export channels to Europe, Latin America and Australia. Key international markets include Germany, the United Kingdom, Austria, Chile and Brazil, facilitated by strategic partnerships and joint ventures. The acquisition of Broken Coast Cannabis Ltd in 2018 expanded the company’s craft cannabis offerings and enhanced its presence in the premium segment.
The company is guided by an experienced management team with backgrounds in agriculture, pharmaceuticals and consumer packaged goods. Aphria completed listings on the Toronto Stock Exchange and Nasdaq before making its securities available in the United States over-the-counter under the symbol APHQF. Looking ahead, the company plans to pursue growth through new product development, regulatory approvals and further strategic alliances.
AI Generated. May Contain Errors.